Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Study Details
Study Description
Brief Summary
The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Early Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: A: Continuous Vismodegib Participants will receive continuous 150 mg by mouth daily vismodegib as per commercially available package insert. |
Drug: Vismodegib 150 MG Oral Capsule
Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Other Names:
|
| Experimental: Arm B: Fixed Intermittent Vismodegib Participants will receive intermittent 150 mg dose vismodegib by mouth with a 12 weeks on/8 weeks off regimen. Participants will take vismodegib for first 12 weeks, then off 8 weeks, and alternate in fixed cycles. |
Drug: Vismodegib 150 MG Oral Capsule
Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Other Names:
|
| Experimental: Arm C: Personalized Intermittent Vismodegib (Adaptive) Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on specific model. |
Drug: Vismodegib 150 MG Oral Capsule
Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Other Names:
|
| Experimental: Arm D: Personalized Intermittent Vismodegib (TGI model) Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on TGI model. |
Drug: Vismodegib 150 MG Oral Capsule
Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Time to Treatment Failure [Up to 36 months]
Time to treatment failure (defined as the time from the day of first dose of study drug to the first day of treatment with another regiment or with the same regimen in a non-adaptive fashion) or a personalized vs fixed intermittent vs continuous dosing of vismodegib.
Secondary Outcome Measures
- Overall Response Rate [Up to 36 months]
Overall Response Rate (ORR) is defined as the rate of the best overall response as complete response (CR) or partial response (PR). ORR will be measured using composite response criteria using RECIST 1.1 and/or externally visible tumors evaluated by bi-dimensional digital medical photography (WHO criteria).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with a cytologically or histologically confirmed locally advanced basal cell carcinoma. (Nodal involvement permitted)
-
Adult males or females 18 years of age or older at time of signing informed consent. All races and ethnicities are eligible, and no upper limit of age is specified.
-
Must have ability to comprehend and the willingness to sign written informed consent for study participation.
-
Patients must have at least one cutaneous tumor site amenable to direct and accurate measurement by ruler/calipers.
-
Patients may have received prior hedgehog inhibitor therapy (if more than 6 months prior) or other systemic treatments for basal cell carcinoma in the past.
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
-
Agreement not to donate blood or blood products during the study and for 24 months after discontinuation of vismodegib.
-
Patients must have adequate hepatic, renal, and bone marrow function as defined in the protocol.
-
Participants must have a negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥1 year.
-
Women of reproductive potential are required to use two forms of acceptable contraception (including one acceptable barrier method with spermicide) during therapy and for 24 months after completing therapy.
-
Female patients must agree not to become pregnant or donate lactation during treatment and until 24 months after stop of treatment. Male patients must use condoms at all times, even after a vasectomy, during sexual intercourse with female partners of reproductive potential during treatment with vismodegib and for 3 months after the last dose to avoid exposing a pregnant partner and unborn fetus to vismodegib. Male patients must agree not to donate sperm during the study and for 3 months after discontinuation of vismodegib.
Exclusion Criteria:
-
Received prior hedgehog inhibitor therapy in the last 6 months
-
Female patients who are pregnant, intend to become pregnant or are nursing.
-
Uncontrolled intercurrent illness including, but not limited to, serious infection. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
-
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment.
-
Inability or unwillingness to swallow capsules.
-
Any known allergy, hypersensitivity or severe reaction to vismodegib or any of the ingredients
-
Co-treatment with a statin or St. John's Wort.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Moffitt Cancer Center | Tampa | Florida | United States | 33617 |
Sponsors and Collaborators
- H. Lee Moffitt Cancer Center and Research Institute
- Genentech, Inc.
Investigators
- Principal Investigator: Zeynep Eroglu, MD, Moffitt Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- MCC 21997